From these results and the results they posted in march on the 12 week trial, I am trying to see what all the excitement is about here.
The likely reason for the difference was in the first study (ELECTRON) 44% of of patients had the IL28B CC polymorphism.
The second study (QUANTUM) only had 16 percent of the patients with CC.
Yes, there are many non-interferon drugs in trials. But Gilead GS-7977 is the furthest along in trials. Which is why it is expected to be the first to market.
Cheers!
Hector
Thanks for the link.
9 of 9 cleared the virus in the first study with GS-7977 and Ribavirin yet only 53% people had a similar response in the 2nd study. (???)
Another interesting aspect I never picked up in the past is just how many companies are competing to come up with new generation HCV treatments: A whopping seven: Gilead, Abbott, Bristol-Myers, Squibb, J&J, Merck and Vertex.